Biogen

Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024

Retrieved on: 
Tuesday, February 27, 2024
Master of Science, PD, Doctor of Philosophy, Medical school, GBA, Alpha-synuclein, Conference, EMBA, Parkinson's disease, Medical University of Innsbruck, Biomarker, Mayo Clinic, Multiple system atrophy, Patient, Dementia, Synucleinopathy, Development, DSM-IV codes, Lewy body, Biogen, Management

MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.

Key Points: 
  • MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.
  • Maria Maccecchini, PhD, Founder, President, and CEO of Annovis, will join a forum discussion focused on new approaches for alpha-synuclein (αSyn), LRKK2, and GBA pathologies.
  • Aggregated αSyn is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
  • It is present in a number of other neurodegenerative diseases and is responsible for axonal impairment and synaptic degeneration.

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

Retrieved on: 
Friday, February 23, 2024
Fever, European Commission, EMA, ALS, Committee, MND, Myalgia, Intracranial pressure, BIIB, Cerebrospinal fluid, Pain, Hope, Biogen, European, SOD1, Arthralgia, Civil service commission, Biomarker, Fatigue, CHMP, AFL, European Medicines Agency, Protein, Disease, UZ Leuven, Mutation, Myelitis, Neurology, Aseptic meningitis, Research, Chronic pain, Vaccine

If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).

Key Points: 
  • If authorized by the European Commission (EC), QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).
  • “The CHMP’s positive opinion reinforces the impact QALSODY can have in SOD1-ALS and further demonstrates Biogen’s commitment to address the unmet needs of people living with ALS and neuromuscular diseases,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen.
  • Trends towards improvement in the physical abilities of participants who received QALSODY were seen compared to those who received placebo, as measured by the ALS Functional Ratings Scale-Revised (ALSFRS-R).
  • Serious neurologic events, including myelitis and/or radiculitis; papilledema and elevated intracranial pressure; and aseptic meningitis have also been reported.

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, February 22, 2024
BRAF, PD, Research, International Myeloma Foundation, Sale, Lung cancer, Workforce, Poster, Melanoma, P-value, Clinical trial, ATM, BCMA, Therapy, CCCC, Roche, Completeness, CRC, AACR, Conference, Colorectal cancer, Merck, NHL, Research and development, Cancer, Dexamethasone, Administration, Patient, Finance, Biogen, Pharmaceutical industry

WATERTOWN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended December 31, 2023, as well as recent business updates.

Key Points: 
  • As of February 2024, three escalation cohorts are complete and dose escalation continues with a fourth dose level currently enrolling.
  • In December 2023, C4T and Merck entered into a license and research collaboration to discover and develop degrader antibody conjugates.
  • Net loss per share for the year ended December 31, 2023 was $2.67, compared to $2.62 for the year ended December 31, 2022.
  • Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities as of December 31, 2023 were $281.7 million, compared to $337.1 million as of December 31, 2022.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors

Retrieved on: 
Friday, February 23, 2024
Class Action Lawsuit, Professional Services, Legal, Biogen, GPM, News, DOJ, Person, BIIB

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB ) investors concerning the Company’s possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB ) investors concerning the Company’s possible violations of the federal securities laws.
  • If you suffered a loss on your Biogen investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/Biogen-Inc-1/ .
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • Whistleblower Notice: Persons with non-public information regarding Biogen should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors

Retrieved on: 
Thursday, February 22, 2024
Class Action Lawsuit, Professional Services, Legal, Biogen, News, DOJ, Suite, BIIB, Telephone

Law Offices of Howard G. Smith announces an investigation on behalf of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB ) investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB ) investors concerning the Company’s possible violations of federal securities laws.
  • On February 14, 2024, Biogen disclosed that it had received a subpoena from the DOJ seeking information about its “business operations in several foreign countries.” On this news, Biogen’s stock price fell $5.91, or 2.6%, to close at $220.74 per share on February 14, 2024, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240222700198/en/

The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors

Retrieved on: 
Thursday, February 22, 2024
Class Action Lawsuit, Professional Services, Legal, Biogen, News, DOJ, Suite, Law, BIIB

The Law Offices of Frank R. Cruz announces an investigation of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB ) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB ) on behalf of investors concerning the Company’s possible violations of federal securities laws.
  • If you are a shareholder who suffered a loss, click here to participate.
  • If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

70 companies unite to launch Tent UK, a new coalition of businesses committed to connecting refugees to work

Retrieved on: 
Tuesday, March 5, 2024
The Adecco Group, IHG Hotels & Resorts, Virginity, Compass Group, GSK, Education, Moody's Investors Service, Pret a Manger, Arcadis, Cooperative, Admiral Group, AA, Salesforce, Ageing, IKEA, DLA Piper, Bank, Health, Methodology, Linklaters, EBay, Dow Jones, Microsoft, Partnership, International, Woman, Ben & Jerry's, Thames Water, Cisco, Lineage Logistics, Accenture, Automation, Employment, Starbucks, Bank of America, Research, Bloomberg, Kraft Heinz, Visa, Government, Pret, Data, John Menzies, Foodservice, McDonald's, ISS, Ipsos, BP, Sanofi, HR, Citigroup, Piper, Biogen, Creative industries

LONDON, March 5, 2024 /PRNewswire/ -- The Tent Partnership for Refugees (Tent) – a global network of companies committed to the labour market integration of refugees – is announcing the launch of Tent UK , a coalition of 70 major companies committed to hiring refugees and helping them become job ready.

Key Points: 
  • LONDON, March 5, 2024 /PRNewswire/ -- The Tent Partnership for Refugees (Tent) – a global network of companies committed to the labour market integration of refugees – is announcing the launch of Tent UK , a coalition of 70 major companies committed to hiring refugees and helping them become job ready.
  • Tent is uniquely placed and ready to help companies develop ambitious programmes to include refugees."
  • "Tent is immensely proud to have brought together 70 leading businesses resolved to connect refugees to meaningful employment," said Jen Stobart, UK Director at Tent.
  • Tent UK is Tent's sixth national coalition to launch, adding to existing coalitions in Canada, France, Mexico, Spain and the United States.

Alexandria Real Estate Equities, Inc. Continues Its Distinctive, Steadfast and Positive Impact on the Widespread and Complex Mental Health Crisis

Retrieved on: 
Tuesday, February 27, 2024
DSM-IV codes, Mental health, FDA, Suicide, Injury, Mental, Mental disorder, Social responsibility, Health, Attention, Human, Biomarker, Therapy, Ecosystem, Public, Policy, Depression, AAA, National Alliance, Patient, Veteran, Military personnel, Congress, Navy, Heart, Trauma, Alexandria Real Estate Equities, Investment, Addiction, Biogen, Partnership, Nursing

PASADENA, Calif., Feb. 27, 2024 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science mega campuses in AAA innovation cluster locations, continues to make a distinctive, steadfast and positive impact on the widespread and complex mental health crisis through one of the company's bedrock social responsibility pillars that prioritizes this unprecedented crisis. With more than 1 in 5 American adults living with a mental illness and over 50,000 suicides in the United States in 2023, including over 6,000 veterans who die by suicide annually, the nation's shared societal responsibility to drive forward treatments and solutions to this devastating public health challenge is immense. The National Alliance on Mental Illness estimates that untreated mental illness represents an economic burden to the nation of over $300 billion each year — a number that understates the true costs of these conditions for those afflicted as well as for their families and society.

Key Points: 
  • "The staggering yet often overlooked mental health crisis in our country is the defining public health challenge of our time.
  • Our Alexandria Summit on Mental Health will set an agenda to drive significant reform, catalyze new mission-critical public-private partnerships and influence policy to accelerate innovation that saves lives."
  • Mental health issues often co-occur with substance use issues, with roughly 50 percent of individuals with severe mental disorders also impacted by addiction.
  • Military personnel and veterans experience mental health and addiction issues at dramatically higher rates than the general U.S. population.